title: Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret®) in a case of refractory Sweet's syndrome.
abstract: Sweet's syndrome is a neutrophilic dermatosis characterized by fever, an elevated neutrophil count, and painful erythematous cutaneous lesions. Histopathological analysis reveals a neutrophilic dermal infiltrate. Systemic corticosteroid therapy remains the mainstay of treatment. We report the case of a 66-year-old male patient who had a 5-year history of Sweet's syndrome refractory to various conventional treatments. Anti-interleukin-1 receptor antagonist anakinra was initiated and this resulted in a dramatic clinical and biological improvement. Anakinra is a promising treatment for neutrophilic dermatoses and sheds light on the interleukin-1/inflammasome pathway as central in the physiopathology of neutrophilic dermatosis.
authors.affiliation: Service de Dermatologie, Hôpital Saint-Eloi, CHU de Montpellier, Université Montpellier I, Montpellier, France. nicolaskluger@yahoo.fr
authors.forename: Nicolas
authors.initials: N
authors.lastname: Kluger
authors.forename: Déborah
authors.initials: D
authors.lastname: Gil-Bistes
authors.forename: Bernard
authors.initials: B
authors.lastname: Guillot
authors.forename: Didier
authors.initials: D
authors.lastname: Bessis
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D003078:Colchicine / Q000008:administration & dosage; D003622:Dapsone / Q000008:administration & dosage; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D009504:Neutrophils / Q000187:drug effects / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors*; D000069283:Rituximab; D016463:Sweet Syndrome / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D003879:Dermatologic Agents; D053590:Interleukin 1 Receptor Antagonist Protein; D017472:Receptors, Interleukin-1; D000069283:Rituximab; D003622:Dapsone; D003078:Colchicine; D011241:Prednisone; D008727:Methotrexate